2013

San Francisco, Calif., December 11, 2013 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and Cynvenio Biosystems, Inc., a cancer diagnostics company, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided […]

San Francisco, Calif., November 13, 2013 – CollabRx, Inc. (the “Company”) (NASDAQ: CLRX) today announced financial results for the second quarter of fiscal year 2014, which ended September 30, 2013. Though subsequent to the end of the second quarter, CollabRx announced a multi-year, non-exclusive agreement with Quest Diagnostics (NYSE:DGX) to provide medical and scientific content […]

San Francisco, Calif., September 4, 2013 – CollabRx, Inc. (NASDAQ: CLRX) today announced the appointment of George Lundberg, M.D. as its Chief Medical Officer. Dr. Lundberg will continue in his position as Editor-in-Chief and Chair of the Editorial Advisory Board of CollabRx. Dr. Lundberg has more than 30 years combined experience as Editor-in-Chief of JAMA […]

San Francisco, Calif., August 13, 2013 – CollabRx, Inc. (the “Company”) (NASDAQ: CLRX) today announced financial results for the first quarter of fiscal year 2014, which ended June 30, 2013. First Quarter Business Highlights Throughout the first fiscal quarter, the Company made significant progress in building revenues and increasing its commercial reach through several agreements and […]

San Francisco, August 13, 2013 – CollabRx, Inc. (NASDAQ: CLRX), a healthcare information technology company focused on informing clinical decision making in molecular medicine, today announced a multi-year agreement with Everyday Health’s MedPage Today, the leading provider of real-time breaking medical news for healthcare professionals. A division of the leading digital health and wellness media […]

San Francisco, Calif., August 8, 2013 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, today announced the launch of the company’s Genetic Variant Annotation™ (GVA™) service. The GVA service is a new product and the company’s first offering for the clinical laboratory market. CollabRx will […]

SAN FRANCISCO, Calif., August 5, 2013 — CollabRx, Inc. (CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, was featured a Forbes article “Can We Build A Kickstarter For Cancer?,” written by Paul Howard. An excerpt from the article stated: Web-based tools and apps (e.g., from CollabRx.com) that can mine […]

SAN FRANCISCO, July 25, 2013 — CollabRx, Inc. (CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announced it has engaged Hayden IR, a 15-year-old, highly recognized, national investor relations firm, to raise the visibility of CollabRx and strengthen its relationships with the investment community “Over the past year, we […]